Status:
COMPLETED
Dapagliflozin Effects on Coronary Calcium and Epicardial Fat Assessed by Cardiotomography
Lead Sponsor:
Hilda Elizabeth Macías Cervantes
Conditions:
Diabete Type 2
Unstable Angina
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
Calcification of the coronary arteries is a direct sign of atherosclerotic disease of the coronary arteries and has been shown to be a strong predictor of the risk of cardiovascular diseases, includin...
Detailed Description
It is now well recognized that Coronary Artery Disease (CAD) is part of the spectrum of cardiovascular diseases (CVDs) that have common underlying risk factors and may manifest as myocardial infarctio...
Eligibility Criteria
Inclusion
- Male and female patients over 18 years of age
- Who meet the criteria of the fourth definition of infarction with and without ST segment elevation
- Known with diabetes mellitus 2 or newly diagnosed diabetes according to ADA criteria
Exclusion
- Patients diagnosed with Type 1 Diabetes Mellitus
- Patients on chronic replacement therapy for renal function using peritoneal dialysis or hemodialysis or with GFR less than 30 ml / min / 1.73m2
- Patients who have recently undergone immunosuppressive therapy
- Patients with a history of recurrent urinary tract infection
- Patients known to be allergic to SGLT-2 inhibitors
- Patients presenting as sudden aborted death.
- Patients who after percutaneous coronary intervention require orotracheal intubation or present a state of shock
Key Trial Info
Start Date :
June 21 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT05998525
Start Date
June 21 2021
End Date
June 1 2023
Last Update
August 21 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Unidad Medica de Alta Especialidad No. 1, Bajío
León, Guanajuato, Mexico, 37260,